RAPP (STOCKS)
Rapport Therapeutics, Inc. Common Stock
$36.254600
-2.145400 (-5.59%)
Prev close: $38.400000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Abraham N. Ceesay
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,831.53M
- Employees
- 69
- P/E (TTM)
- -14.70
- P/B (TTM)
- 3.89
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
10
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.42 | $-0.68 | +0.2642 | +38.61% |
|
Dec 2025 (Q4)
|
$-0.72 | $-0.69 | -0.0284 | -4.11% |
|
Sep 2025 (Q3)
|
$-0.71 | $-0.79 | +0.0809 | +10.23% |
|
Jun 2025 (Q2)
|
$-0.75 | $-0.85 | +0.0983 | +11.59% |
Financial Statements
| Revenues | $20.00M |
| Nonoperating Income/Loss | $14.93M |
| Operating Expenses | $142.21M |
| Research and Development | $107.93M |
| Operating Income/Loss | -$122.21M |
| Income/Loss From Continuing Operations After Tax | -$107.28M |
| Income/Loss From Continuing Operations Before Tax | -$107.28M |
| Net Income/Loss | -$107.28M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$107.28M |
| Net Income/Loss Available To Common Stockholders, Basic | -$107.28M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.59 |
| Diluted Earnings Per Share | -$2.59 |
| Basic Average Shares | 123,323,105 |
| Diluted Average Shares | 123,323,105 |
| Assets | $497.60M |
| Current Assets | $484.70M |
| Cash | $476.80M |
| Other Current Assets | $7.90M |
| Noncurrent Assets | $12.90M |
| Fixed Assets | $2.52M |
| Other Non-current Assets | $10.38M |
| Liabilities | $26.09M |
| Current Liabilities | $17.90M |
| Accounts Payable | $6.56M |
| Wages | $3.08M |
| Other Current Liabilities | $8.26M |
| Noncurrent Liabilities | $8.19M |
| Equity | $471.51M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $471.51M |
| Liabilities And Equity | $497.60M |
| Net Cash Flow From Operating Activities | -$80.30M |
| Net Cash Flow From Operating Activities, Continuing | -$80.30M |
| Net Cash Flow From Investing Activities | -$170.56M |
| Net Cash Flow From Investing Activities, Continuing | -$170.56M |
| Net Cash Flow From Financing Activities | $271.31M |
| Net Cash Flow From Financing Activities, Continuing | $271.31M |
| Net Cash Flow | $20.45M |
| Net Cash Flow, Continuing | $20.45M |
| Comprehensive Income/Loss | -$107.71M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$107.69M |
| Other Comprehensive Income/Loss | -$27.35M |
| Other Comprehensive Income/Loss Attributable To Parent | -$410.00K |